Guardant Health • 25%

Roche • 25%

Illumina • 25%

Other • 25%

Less than 20% • 25%

20% to 30% • 25%

30% to 40% • 25%

More than 40% • 25%

Guardant Health becomes the market leader • 25%

Guardant Health is among the top 3 • 25%

Guardant Health remains in the top 5 • 25%

Guardant Health does not make it to the top 5 • 25%

Manufacturer A has largest share • 25%

Manufacturer B has largest share • 25%

Manufacturer C has largest share • 25%

Manufacturer D or others have largest share • 25%

Market share increases • 25%

Market share remains the same • 25%

Market share decreases • 25%

Foresight exits cancer-detection market • 25%

Below 10% • 25%

10% - 20% • 25%

20% - 30% • 25%

Above 30% • 25%

New test leads market • 25%

Existing tests maintain dominance • 25%

Market share evenly distributed • 25%

Other outcome • 25%

Manufacturer A • 25%

Manufacturer B • 25%

Manufacturer C • 25%

Other • 25%

Tecentriq Hybreza gains the most market share • 25%

Keytruda gains the most market share • 25%

Opdivo gains the most market share • 25%

Other treatment gains the most market share • 25%

Yes • 50%

No • 50%

Yes • 50%

No • 50%

Yes • 50%

No • 50%